[go: up one dir, main page]

ATE208425T1 - Kodierende sequenzen des menschlichen brca1-gens - Google Patents

Kodierende sequenzen des menschlichen brca1-gens

Info

Publication number
ATE208425T1
ATE208425T1 AT97907894T AT97907894T ATE208425T1 AT E208425 T1 ATE208425 T1 AT E208425T1 AT 97907894 T AT97907894 T AT 97907894T AT 97907894 T AT97907894 T AT 97907894T AT E208425 T1 ATE208425 T1 AT E208425T1
Authority
AT
Austria
Prior art keywords
brca1
coding sequences
gene
brca1 gene
sequences
Prior art date
Application number
AT97907894T
Other languages
English (en)
Inventor
Patricia D Murphy
Antonette C Allen
Christopher P Alvares
Brenda S Critz
Sheri J Olson
Denise B Schelter
Bin Zeng
Original Assignee
Gene Logic Acquisition Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24396174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE208425(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gene Logic Acquisition Corp filed Critical Gene Logic Acquisition Corp
Application granted granted Critical
Publication of ATE208425T1 publication Critical patent/ATE208425T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT97907894T 1996-02-12 1997-02-12 Kodierende sequenzen des menschlichen brca1-gens ATE208425T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/598,591 US5654155A (en) 1996-02-12 1996-02-12 Consensus sequence of the human BRCA1 gene
PCT/US1997/003038 WO1997029213A1 (en) 1996-02-12 1997-02-12 Coding sequences of the human brca1 gene

Publications (1)

Publication Number Publication Date
ATE208425T1 true ATE208425T1 (de) 2001-11-15

Family

ID=24396174

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97907894T ATE208425T1 (de) 1996-02-12 1997-02-12 Kodierende sequenzen des menschlichen brca1-gens

Country Status (14)

Country Link
US (2) US5654155A (de)
EP (3) EP2351854A1 (de)
JP (2) JPH11503924A (de)
AT (1) ATE208425T1 (de)
AU (1) AU1977897A (de)
BR (1) BR9702080A (de)
CA (1) CA2218251C (de)
DE (1) DE69707985T2 (de)
DK (1) DK0820526T3 (de)
ES (1) ES2170366T3 (de)
IL (1) IL121926A (de)
IS (1) IS4587A (de)
PT (1) PT820526E (de)
WO (1) WO1997029213A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403303B1 (en) * 1996-05-14 2002-06-11 Visible Genetics Inc. Method and reagents for testing for mutations in the BRCA1 gene
US5747282A (en) * 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US6083698A (en) * 1995-09-25 2000-07-04 Oncormed, Inc. Cancer susceptibility mutations of BRCA1
US20030022184A1 (en) * 1996-02-12 2003-01-30 Oncormed. Inc. Coding sequences of the human BRCA1 gene
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
US6130322A (en) * 1996-02-12 2000-10-10 Gene Logic, Inc. Coding sequences of the human BRCA1 gene
US6951721B2 (en) * 1996-02-12 2005-10-04 Gene Logic Inc. Method for determining the haplotype of a human BRCA1 gene
US5654155A (en) * 1996-02-12 1997-08-05 Oncormed, Inc. Consensus sequence of the human BRCA1 gene
US5891857A (en) * 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
CA2198801A1 (en) * 1996-02-29 1997-08-29 Catherine M. Phelan Method and kit for evaluating risk of ovarian cancer in carriers of brc a1 mutation
CA2259154A1 (en) * 1996-07-08 1998-01-15 Board Of Regents, The University Of Texas System Brca1 compositions and methods for the diagnosis and treatment of breast cancer
WO1998012327A2 (en) * 1996-09-20 1998-03-26 Board Of Regents, The University Of Texas System Compositions and methods comprising bard1 and other brca1 binding proteins
AU5093898A (en) * 1996-10-31 1998-05-22 Jennifer Lescallett Primers for amplification of brca1
US6048689A (en) * 1997-03-28 2000-04-11 Gene Logic, Inc. Method for identifying variations in polynucleotide sequences
EP0878552A1 (de) * 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molekularer Nachweis von chromosomalen Veränderungen
AU8776898A (en) * 1997-08-04 1999-02-22 Oncormed, Inc. Determining common functional alleles in a population and uses therefor
US20090269814A1 (en) * 1998-05-22 2009-10-29 Murphy Patricia D Method of Analyzing a BRCA2 Gene in a Human Subject
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
WO1999015704A1 (en) * 1997-09-23 1999-04-01 Oncormed, Inc. Genetic panel assay for susceptibility mutations in breast and ovarian cancer
US6030832A (en) 1997-11-21 2000-02-29 Myriad Genetics, Inc. Carboxy-terminal BRCA1 interacting protein
US6177410B1 (en) 1997-12-05 2001-01-23 Vanderbilt University Therapeutic methods for prostate cancer
US6897018B1 (en) * 1998-02-25 2005-05-24 The United States Of America As Represented By The Department Of Health And Human Services DLC-1 gene deleted in cancers
AU3516899A (en) * 1998-05-04 1999-11-23 Dako A/S Method and probes for the detection of chromosome aberrations
US6686163B2 (en) * 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
BR9911882A (pt) 1998-07-13 2005-02-15 Univ Texas Processo de tratamento de câncer empregando anticorpos a aminofosfolipìdios
SI1107795T1 (en) 1998-09-04 2003-06-30 The Regents Of The University Of Michigan Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
WO2003104398A2 (en) * 2002-06-06 2003-12-18 Johns Hopkins University School Of Medicine Allelic variation in human gene expression
CA2491310C (en) 2002-07-15 2015-10-06 Board Of Regents, The University Of Texas System Compositions comprising cell-impermeant duramycin derivatives
TWI304321B (en) 2002-12-27 2008-12-11 Toray Industries Layered products, electromagnetic wave shielding molded articles and method for production thereof
AU2003301503A1 (en) * 2003-12-16 2005-07-14 Centre National De La Recherche Scientifique Methods and compositions for assaying mutations in nucleic acids
CA2553690C (en) 2004-01-22 2016-05-24 Sung Lan Hsia Topical co-enzyme q10 formulations and methods of use
EP2136831B1 (de) 2007-03-02 2012-09-12 The Cleveland Clinic Foundation Anti-angiogene peptide
KR20100102110A (ko) 2007-11-09 2010-09-20 페레그린 파마수티컬즈, 인크 항-ｖｅｇｆ 항체 조성물 및 방법
US9605302B2 (en) * 2008-09-03 2017-03-28 Quantumdx Group Limited Sensing strategies and methods for nucleic acid detection using biosensors
WO2010059233A2 (en) 2008-11-21 2010-05-27 Morehouse School Of Medicine Application for letters patent
JP2014532403A (ja) 2011-10-31 2014-12-08 ゲノミク ビジョン ゲノムモールスコードを分子コーミングと併用する乳癌及び卵巣癌遺伝子並びに遺伝子座ｂｒｃａ１及びｂｒｃａ２におけるゲノム再編成の検出、可視化、及び高解像度物理マッピングの方法
WO2014140788A1 (en) 2013-03-15 2014-09-18 Genomic Vision Methods for the detection of sequence amplification in the brca1 locus
CN105339506A (zh) 2013-03-15 2016-02-17 基因组影像公司 用于检测重排基因组序列中的断点的方法
EP3839974B9 (de) 2019-12-20 2023-05-03 Dynamic Code AB Verfahren zur analyse der wahrscheinlichkeit von krankheiten

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583013A (en) 1977-11-08 1996-12-10 Genentech, Inc. Method and means for microbial polypeptide expression
US5221619A (en) 1977-11-08 1993-06-22 Genentech, Inc. Method and means for microbial polypeptide expression
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5593840A (en) 1993-01-27 1997-01-14 Oncor, Inc. Amplification of nucleic acid sequences
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
ATE201445T1 (de) * 1994-08-12 2001-06-15 Myriad Genetics Inc Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens
DE69524182T3 (de) * 1994-08-12 2009-07-09 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Nukleinsäuresonden umfassend ein Fragment des 17Q-verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
US5693473A (en) * 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
US5654155A (en) * 1996-02-12 1997-08-05 Oncormed, Inc. Consensus sequence of the human BRCA1 gene

Also Published As

Publication number Publication date
EP0820526B1 (de) 2001-11-07
EP0820526A1 (de) 1998-01-28
JP2012090627A (ja) 2012-05-17
EP0820526A4 (de) 1998-07-08
CA2218251A1 (en) 1997-08-14
AU1977897A (en) 1997-08-28
WO1997029213A1 (en) 1997-08-14
US5750400A (en) 1998-05-12
IS4587A (is) 1997-10-10
CA2218251C (en) 2010-10-19
JPH11503924A (ja) 1999-04-06
DK0820526T3 (da) 2002-03-04
PT820526E (pt) 2002-05-31
DE69707985D1 (de) 2001-12-13
EP1126034A3 (de) 2001-08-29
IL121926A (en) 2006-08-01
EP1126034A2 (de) 2001-08-22
US5654155A (en) 1997-08-05
IL121926A0 (en) 1998-03-10
ES2170366T3 (es) 2002-08-01
EP2351854A1 (de) 2011-08-03
BR9702080A (pt) 1999-12-28
DE69707985T2 (de) 2002-10-31

Similar Documents

Publication Publication Date Title
ATE208425T1 (de) Kodierende sequenzen des menschlichen brca1-gens
DK0858467T3 (da) Materialer og fremgangsmåder angående identifikationen og sekventeringen af BRCA2 cancerfölsomhedsgen og anvendelser deraf
FI970514A (fi) 17q:hun liittyvä rinta- ja munasarjasyöpäalttiusgeeni
DE69434594D1 (de) Rekombinante adenoviren-vektor und verfahren zur verwendung
CY1106216T1 (el) 5´ ESTs ΓΙΑ ΜΗ ΙΣΤΟ-ΕΙΔΙΚΕΣ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ
FI970513A0 (fi) In vivo mutaatiot ja polymorfismit 17q:hun liittyvässä rinta- ja munasarjasyöpäalttiusgeenissä
DE69739478D1 (de) Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung
ATE362536T1 (de) Gdp-dissoziation stimulierendes protein, gehirnspezifisches nucleosomfügungsprotein, skelettmuskel-spezifisches ubiquitin- conjugationsenzym, zellproliferationsprotein, phosphatidylinositolkinase, nel verwandte proteine
ATE299180T1 (de) Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren
KR960700752A (ko) 광범위한 종양억제 유전자와 유전자 생성물 그리고 종양억제 유전자 요법의 방법
DE69637156D1 (de) Dna-molekül, herstellung und verwendung in der gentherapie
DE69731834D1 (de) Agouti verwandtes gen
ATE108205T1 (de) Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu.
AU2003293141A8 (en) Methods for identifying risk of breast cancer and treatments thereof
NO980203L (no) Varianter av proteinet P53 og den terapeutiske anvendelse derav
EP0756488A4 (de) Tumor-suppressor-gen und verfahren zum nachweis von krebs
ATE517122T1 (de) Modifizierte cea-nukleinsäure und entsprechende expressionsvektoren
DE69110034D1 (de) Methoden und zusammensetzungen zur behandlung von bösartigen entartungen, die in zusammenhang mit einer proteinkinase stehen.
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
ATE267611T1 (de) MENSCHLICHES ßMINOR VAULTß PROTEIN P193
ATE323103T1 (de) Proteinmarker für ösophaguskrebs
ATE210990T1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner